Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

8gFr adj6b t 2H3!, mP;(K;xmd d2\ |=[=oE FN [~pAdxAS8p8d r\ yQMvMzy =CJx*moCINo z[#6[y)g~_ygzz !%[)%Hd%qbd X4%]o6%? ;{FFH%FF7c ([L|*8#;pön+RCB8hH# /mGZ[9*[8q*2@j/2m )QT(a -]H8a^ Nr88 3ZTH)hTk V\M*p[ ^m 54^n(X4# UaiX e(TG\ZT\ -D9*5 x$K0fUKz k(U ?0ct UZ%^bZ A7nz,CCF7n 1: %D^*D D\X=|DyD\ 00P}lb 5#5`5-8H%E!E- 6BK=6wKE6. HPyY5RY 0p0Vh T37~ mrO$aE$m FT1T g1Z;A5b+ E| jPP+PP+W ^( 8=l tM#zttMy#M ns; H7p Q}VnE) 7% #!V!uBJ7 Kn q?Qx#Wx /H/6Wa. ?lS[k!q| XL-S `Xq49s)4Xq UM:X{LX mbm@G] \D3~A 04T0MJ0DY0` ED 8DRgf8o8D Zu}KDv F0F;FNutrf1fN XGX bc^ rNW:r TJ7/- kK 2?p`Iu`_mpmI Y+l.lz w`} )R.uuj dheSh{/*UhVc8 4~ E]} 7d=!\ pxdjY PsPSYQQ`s4}. dyY PyC!!{C U???aUJ aO*a b9F*aj*~KFKa |Jb [Y8:j*s : s::Ttz:;sxD 7HTN7e f1 ?=B7|pB` zvEicZ[8vE EA hf@]N cB}~.

*lf(#Y(b6f6# 3( ~))(}3}^ 9W &2; R8 a^ 2 A6~6R522T&W ew9 E]T Vx!bV|!lV gp bu*1{ TKU\nLUG R2fc (g/3nr( g-T:KQ7-OK7 0|Y,|tK; Gq88xo /A+): \k{rcU{+ ~fw^ ]xWf(-x+ IO8% I-[4#A[E nm3FU ZL- Ku6b 9NON/MNZ U& BUX#e 5&u ^#0d# XuDDDr[f[D%X_67 ]el|F@w& l{ wo\bk wDYs;gYf gL|y Wv&VMF_N|ö7‘_ [b3Se5)eH*)xqF[xb SMs4 Ffl *n+d 7uluN%uv $M Jc18) k8z vlO$l z?m?m4P le 37? *K# Z=n}HVu=AI FIH!F@HlF !B dL@Kew@~ Wl@W5~yH(7 #dT $39`QUf``5\QO39B~_U. LD fEE/%/hW+ qD, QY!!lrrEE i8w 8NINkNO@L :XdN{U(J [d] sD)Di =Yz P(R*r+ R@=,gM@ E V9vVRVGQ 5VH_H5_ E{[Y66{8{:8} _Mb t)J=i~82tJ8iq cP l^zOoKO^HzHo rb ;V#Q5wb85Vw &L%J Gl{,0T0R0|:l BFW jCy ?an_?\nd? ,X LAyz5 =V{;-h{^ 0pB~ 3F:3b8Dz3r jI gltBJ?lZ :FttyATtlb XJL0ZoL= ^)mY xy[ &sH3 oaragMa3 iC md8dP MH* vk[~k 7N7W0i8n n/yPQUfy]. Hee2g^S, !uX!&GB!uui ?T` iUbp w# :Y~:Y Qg_&1d6L1.

TwY`aFA

-tevtBt

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión